Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H17ClN2O |
Molecular Weight | 300.783 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCNC1=NC2=CC=C(Cl)C=C2[C@](C)(O1)C3=CC=CC=C3
InChI
InChIKey=IBYCYJFUEJQSMK-QGZVFWFLSA-N
InChI=1S/C17H17ClN2O/c1-3-19-16-20-15-10-9-13(18)11-14(15)17(2,21-16)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3,(H,19,20)/t17-/m1/s1
DescriptionSources: https://www.google.ch/patents/WO2007109288A3
Sources: https://www.google.ch/patents/WO2007109288A3
(R)-Etifoxine is an isomer, chemically isolated from Etifoxine (Stresam), an approved racemic drug (off patent) prescribed in Europe. (R)-Etifoxine was developed by Xytis Inc for treatment pain, mental disease, and central nervous system disorders. However future development has been discontinued.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25589941
Curator's Comment: Data for R/S-Etifoxine
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Sources: https://www.google.ch/patents/WO2007109288A3 |
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.google.ch/patents/WO2007109288A3
50 mg up to about 150 mg/day.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
950522-63-1
Created by
admin on Sat Dec 16 09:41:28 GMT 2023 , Edited by admin on Sat Dec 16 09:41:28 GMT 2023
|
PRIMARY | |||
|
135564606
Created by
admin on Sat Dec 16 09:41:28 GMT 2023 , Edited by admin on Sat Dec 16 09:41:28 GMT 2023
|
PRIMARY | |||
|
5KC5K5SST8
Created by
admin on Sat Dec 16 09:41:28 GMT 2023 , Edited by admin on Sat Dec 16 09:41:28 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD